Differentiation Treatment Applied to Lung Cancer Model Reduces Pathogenic Traits in Vitro
Advanced Biology · 2026
DOI: 10.1002/adbi.202500371 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Biology, 2026. Verfasst von Alice Grossi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, University of Pavia, Pavia, Italy. Hauptthemen laut MEDLINE: Lung Neoplasms, Neoplastic Stem Cells, Carcinoma, Non-Small-Cell Lung, Cell Differentiation. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of University and Research.
Abstract (Originalsprache)
Non‐small cell lung cancer (NSCLC) relapse after therapy is linked to the high aggressiveness, chemoresistance and metastatic potential of tumor cells due, in part, to the presence of cancer stem cells (CSCs). Pro‐differentiation approaches have shown promising results for leukemia and in some solid cancer models, offering a possibility to enhance current anti‐cancer therapies. Here, the human NSCLC line A549 is exposed to a serum‐containing medium supplemented with pro‐differentiation factors (DM), and effects on the cells’ proliferation, migration and adhesion properties are assessed in vitro, alongside CSC marker expression analyzed after treatment in 2D or 3D culture conditions. A549 cells exposed to DM exhibited notable morphological changes, with significant increase in cellular footprint and vesicle accumulation. These phenotypic alterations coincided with significant inhibition of proliferation and migration, whereas adhesion properties increased, similar to alkaline phosphatase activity. DM treatment of A549 cells also caused a significant reduction in clonogenic ability by two thirds, as well as halving anchorage‐independent colony formation and spheroid growth, alongside a reduced expression of stemness markers SOX2, NANOG, CD44 and ABCG2, and of ALDH activity and aquaporin function. These results indicate decreased pathogenic features of NSCLC cells after DM exposure, suggesting that pro‐differentiation treatment may represent a valuable option for further preclinical testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Medicine, University of Pavia, Pavia, Italy.
- Department of Biology and Biotechnology, University of Pavia, Pavia, Italy.
- Centre for Health Technologies (CHT), University of Pavia, Pavia, Italy.
- UOC Bioscaffolds and transplantation, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
ORCID-Profile: Alice Grossi, Monica Savio, Virginie Sottile
Förderung
- Italian Ministry of University and Research
Zitieren
APA
Grossi, A., Fulghieri, P., Aduvaliev, A., Soffiantini, K., Oldrati, I., Cavallo, M., Biggiogera, M., Pellavio, G., Laforenza, U., Savio, M., & Sottile, V. (2026). Differentiation Treatment Applied to Lung Cancer Model Reduces Pathogenic Traits in Vitro. Advanced Biology. https://doi.org/10.1002/adbi.202500371
Vancouver
Grossi A, Fulghieri P, Aduvaliev A, Soffiantini K, Oldrati I, Cavallo M, et al. Differentiation Treatment Applied to Lung Cancer Model Reduces Pathogenic Traits in Vitro. Advanced Biology. 2026. doi:10.1002/adbi.202500371
BibTeX
@article{Grossi2026,
author = {Grossi, Alice and Fulghieri, Paola and Aduvaliev, Abdurakhmon and Soffiantini, Karen and Oldrati, Irene and Cavallo, Margherita and Biggiogera, Marco and Pellavio, Giorgia and Laforenza, Umberto and Savio, Monica and Sottile, Virginie},
title = {Differentiation Treatment Applied to Lung Cancer Model Reduces Pathogenic Traits in Vitro},
journal = {Advanced Biology},
year = {2026},
doi = {10.1002/adbi.202500371}
}
EUVIMED